What is the current stock price of Solid Biosciences Inc.?
Solid Biosciences Inc. (NASDAQ: SLDB) trades at a market price of approximately $8.06 per share. The precision genetic medicine enterprise experiences dynamic valuation adjustments during Nasdaq trading sessions, influenced by clinical trial progress for its neuromuscular disease therapies, regulatory milestones, capital-raising activities, and biotechnology sector sentiment.
Related FAQs
Solid Biosciences Inc, trading under the ticker symbol SLDB, is a clinical-stage genetic medicine biotechnology company focused on developing advanced treatments for rare neuromuscular diseases such as Duchenne muscular dystrophy.
Sophos is not owned by Microsoft, operating instead as an independent global cybersecurity leader specializing in next-generation endpoint and network security solutions.
Tosoh Corporation is a prominent, multinational chemical and specialty materials enterprise headquartered in Tokyo, Japan.
Tosoh Corporation operates as a publicly traded corporate entity, maintaining its primary listing on the Prime Market of the Tokyo Stock Exchange under standard security identifiers.
Tosoh Corporation is a major Japanese chemical and specialty materials manufacturing enterprise headquartered in Tokyo.
Sophos Ltd.
Tosoh America Inc. operates as the North American holding and operational subsidiary of Tosoh Corporation, a major Japanese multinational chemical and advanced materials enterprise.
Tosoh Corporation is a massive Japanese multinational chemical and advanced materials manufacturing enterprise that produces a comprehensive and diverse portfolio of industrial products.
Hemoglobin A1c (HbA1c) measurements performed using the Tosoh A1c 2.2 Plus Analyzer refer to a specific clinical laboratory method used to assess long-term glycemic control in patients with diabetes.
For an individual around 70 years of age without a diagnosis of diabetes, a normal glycated hemoglobin or HbA1c level is typically below 5.7 percent, reflecting healthy average blood glucose control over the preceding three months.
Elevated hemoglobin A1C levels, which reflect chronic high blood glucose over a three-month period, are primarily caused by uncontrolled Type 2 or Type 1 diabetes mellitus.
Sky Bioscience and related early-stage life sciences research entities maintain corporate valuations tied to specialized biotechnology market trends, clinical pipeline progress, private funding rounds, and official regulatory filings rather than s...
SOPHiA GENETICS SA (NASDAQ: SOPH) trades at a market price of approximately $5.67 per share.
Tosoh Bioscience operates as a specialized subsidiary and business unit within the broader multinational chemical and materials group Tosoh Corporation, which trades on the Tokyo Stock Exchange under ticker 4042, meaning its specific division metr...
Sophos Group plc previously traded on the London Stock Exchange under the ticker symbol SOPH as a leading global cybersecurity enterprise specializing in network and endpoint security solutions.
Tosoh Corporation is a major Japanese multinational chemical and specialty materials manufacturing enterprise founded originally in 1935 as Toyo Soda Manufacturing Company.
You should consult a healthcare provider and monitor your hemoglobin A1C levels closely if your test results fall into the prediabetes range between 5.7 percent and 6.4 percent, or reach the diagnostic threshold for diabetes at 6.